Edition:
United States

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

2.90EUR
20 Jan 2017
Change (% chg)

€0.00 (+0.00%)
Prev Close
€2.90
Open
€2.93
Day's High
€2.94
Day's Low
€2.90
Volume
58,603
Avg. Vol
141,396
52-wk High
€3.67
52-wk Low
€1.96

VLS.PA

Chart for VLS.PA

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.98
Market Cap(Mil.): €224.99
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  VLS.PA Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -0.63 -- --
ROI: -23.53 -1.38 14.86
ROE: -38.92 -1.07 16.28

BRIEF-Valneva 9M EBITDA swings to profit of 3.5 million euros

* 9M total revenues and grants grew to 70.7 million euros in first nine months of 2016 (versus. 60.7 million euros in same period of 2015)

Nov 09 2016

BRIEF-Valneva H1 EBITDA turns to 4.7 mln euro profit

* Reports strong revenue growth and positive EBITDA in H1 2016

Aug 31 2016

BRIEF-Valneva to distribute Seqirus' flu vaccines in Austria

* Valneva announces signing of marketing & distribution agreement for Seqirus' flu vaccines Sandovac and Fluad in Austria

Aug 25 2016

BRIEF-Valneva successfully completes Clostridium Difficile phase II trial

* Announces successful completion of phase II for clostridium difficile vaccine candidate

Jul 25 2016

Earnings vs. Estimates